基于MS4A7的代谢基因特征作为肺腺癌的预后预测因子
Yan Jiang1, Zhengyu Shu1, Lei Cheng2,3
1Department of Reproductive Medicine Nursing, Key Laboratory of Birth Defects and Related Disease of Women and Children, West China Second University Hospital, Sichuan University, Chengdu, China.
Frontiers in molecular biosciences
|May 13, 2025
概括
这项研究确定MS4A7是肺腺癌 (LUAD) 预后的关键基因,将其在巨细胞中的表达与代谢变化和免疫相互作用联系起来,具有作为生物标志物和治疗标的潜力.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 代谢过程中的代谢.
背景情况:
- 肺腺癌 (LUAD) 是全球癌症死亡的主要原因.
- 瘤代谢重编程显著影响瘤发生,并创造了一个免疫抑制瘤微环境.
- 与新陈代谢相关的基因在预测LUAD结果方面表现有前途.
研究的目的:
- 为了研究MS4A7在LUAD中的预后价值.
- 探索MS4A7在LUAD免疫微环境中的作用.
- 了解MS4A7,新陈代谢和免疫细胞在LUAD中的相互作用之间的联系.
主要方法:
- 在癌症基因组图谱 (TCGA) RNA-seq数据上使用LASSO-Cox回归开发了LUAD的预后签名.
- 识别了与代谢相关的基因的差异表达,并构建了一个风险特征.
- 利用单细胞RNA测序来分析LUAD巨细胞中的MS4A7表达.
主要成果:
- 一个结合20个与代谢相关的基因的预后模型证明了对LUAD存活的高预测准确性.
- 高风险患者的生存率较低,代谢途径失调,包括糖解和mTORC1信号传递.
- MS4A7主要表达在特定的巨细胞群 (MS4A7+巨细胞) 中,这些巨细胞与T细胞和中性粒细胞进行免疫交叉.
结论:
- MS4A7对于LUAD预后至关重要,它影响瘤微环境中的免疫调节.
- MS4A7+巨细胞表现出独特的代谢重编程和免疫功能,影响LUAD的进展.
- MS4A7为LUAD提供了潜在的预后生物标志物和治疗点,对治疗策略有影响.
更多相关视频
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
990
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
1.4K
相关概念视频
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...